Showing results (51-60 of 132) with videos related to
Sort By:
Pageof 14
Clinical Lung Cancer|July 31, 2017
Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent ChemotherapyMark A Sonnick, Federica Oro, Bernice Yan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvementRenato G Martins, Thomas A D'Amico, Billy W Loo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinibSandra P D'Angelo, Yelena Y Janjigian, Nicholas Ahye, et al.Nature Communications|October 14, 2022
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomasPaul K Paik, Jia Luo, Ni Ai, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 23, 2021
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumabMaria Thor, Annemarie F Shepherd, Isabel Preeshagul, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2024
An <sup>18</sup>F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and ImmunotherapyMaria Thor, Chen Lee, Lian Sun, et al.Cancer Immunology Research|July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLCFernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.JAMA Network Open|January 5, 2023
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and DurvalumabEmily S Lebow, Annemarie Shepherd, Jordan E Eichholz, et al.JCO Precision Oncology|June 21, 2021
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerJoel W Neal, Daniel B Costa, Alona Muzikansky, et al.Pageof 14